Bladder Cancer
Bladder cancer is among the five most common cancers in men. It is a type of cancer that occurs mostly at older ages. In many cases, the first symptoms of bladder cancer, such as hematuria, lead to an early diagnosis, improving the patient's chances of treatment and survival.
As with most cancers, smoking is a major risk factor, as well as some chronic bladder diseases and a family history of bladder cancer.
Conventional treatment offers chemotherapy and radiotherapy options, as well as surgery, which can be as extensive as to lead to complete removal of the bladder depending on how advanced the disease is. The patient's survival depends largely on the stage of the cancer at the time of discovery, as well as its histological type, which determines its more or less aggressive behavior. The goals of these treatments will depend on how advanced the cancer is.
Escozul™ can be administered in conjunction with any conventional treatment. Escozul™ seeks to work not only on the cancer but also on the patient's quality of life. Its analgesic and anti-inflammatory effects help to improve the quality of life in about 65 to 75% of the patients treated. Through its antitumor effect, depending on the stage, one of the following results is expected: to be able to slow down the progression of the disease, to stop tumor growth, to reduce the size of lesions or to eliminate tumor lesions.
It is important to point out that Escozul™ is not considered a cure for cancer, it is a natural medicine that converts this deadly disease into a controlled chronic one, also offering quality of life.
Results in different cases
Bladder cancer with multiple bone metastases. Patient: C.A.M. Age: 54
Patient diagnosed with high grade bladder cancer with multiple bone metastases is in remission.
Read moreC.A.M is a 54-year-old patient, who came to us in January 2018 with a diagnosis of high-grade urothelial carcinoma of the bladder with bone metastases, is declared disease free.
Case summary:
C.A.M is a 54-year-old patient, who came to us in January 2018 with a diagnosis of high-grade bladder carcinoma.
When we received the medical documentation we were able to ascertain that it was an infiltrating, high-grade urothelial carcinoma of the bladder, which had undergone surgery and was undergoing treatment with chemotherapy and immunotherapy. He presented bone metastases in the acetabular roof and left ischiopubic branch that appeared despite receiving the aforementioned treatments and also multiple lesions in the left iliac bone in progression in terms of number. The bladder wall presented thickening of 6mm. She told us that she was very tired and that she was beginning to notice physical deterioration.
Once the case had been analyzed by our specialists, we informed the patient's daughter about what to expect with Escozul™ and the possibilities of achieving good results. High-grade carcinomas tend to behave aggressively and their progression cannot always be stopped or reversed.
Each dose of Escozul™ is personalized, specific to the type of tumor and aggressiveness of the tumor. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.
C.A.M. started treatment with Escozul™ in January 2018. She was pending a change in her chemotherapy treatment.
Evolution, Follow-up and Current Results:
Mr. C.A.M. has been in communication with our medical side reporting the various changes noted during treatment.
At the end of February 2018 he commented to us that he had finally received chemotherapy with a different drug and monoclonal antibodies, due to the poor response to the previous treatment. She also indicated to us that she was feeling better physically and that the pain in her left hip had decreased markedly.
By July 2018, she comments to us that: "my recovery has been very noticeable and even amazing in the opinion of my Oncologist doctor and technicians performing the PET-CT studies". He indicates that the pain in the hip disappeared almost completely, only presenting occasional discomfort in certain positions.
C.A.M. commented to us that in April 2018 the PET-CT performed had found no traces of tumor activity.
The July 2018 PET-CT indicates that there is no evidence of metabolic activity suggestive of malignant tumor pathology. That is, there is no detectable presence by this route anywhere in the organism.
At this time he was left only on immunotherapy treatment by conventional medicine and with respect to Escozul™ we indicated to continue until completion of 6 months post cancer-free examination, before discharge from the protocol.
In this case, the joint use of Escozul™ with chemotherapy and immunotherapy made it possible for C.A.M., in a short period of time, to have a much better result than expected in these cases, which led to his being declared free of the disease at this time.
As we always say, it is important to note that it is not possible to generalize any results with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.
It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.
If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, i.e. it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.
To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.
Prepared by LifEscozul™ Group August/2018
Medical Documents
Invasive bladder cancer Patient: PP Age: 65 years old
Patient with bladder cancer manages to eliminate the disease after 6 months of using Escozul™.
Read morePP is a 65-year-old patient diagnosed with infiltrating bladder cancer. He came to us at the end of August 2016, looking for other treatment options to improve his prospects outcomes and survival.
Case summary:
The case we share today is about a 65-year-old patient who came to us in late August 2016, with a diagnosis of infiltrating bladder cancer.
When we received the medical documentation we were able to ascertain that this was a primary bladder cancer (specifically a poorly differentiated infiltrating urothelial carcinoma), with invasion into the muscular layers of the bladder, subepithelial connective tissue and perineural invasion. According to the degree of differentiation it was a grade 3 cancer, which implies an aggressive behavior of the disease.
Once the case had been analyzed by our specialists, we informed the patient about what to expect with Escozul™ and the possibilities of achieving good results, explaining the case in view of the prospect of an aggressive disease and considering that PP was not receiving other treatments.
Each dose of Escozul™ is personalized, specific to the type of tumor and its aggressiveness. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.
PP started treatment with Escozul™ in September 2016. He was pending to discuss with his physicians the possibility of surgery.
Evolution, Follow-up and Current Results:
PP started treatment with Escozul™ in September and in mid-November also started chemotherapy, as a treatment prior to the proposed bladder surgery.
During this time there have been no complications or symptoms that significantly interfere with PP's health, although he has had discomfort associated with chemotherapy.
In March, a new CT scan of the abdomen and pelvis with contrast was performed, which did not show the presence of the disease in the bladder, nor tumor masses in other parts of the body.
The results in the case of PP, obtained with the combined use of Escozul™ and chemotherapy, have been very good for the time he has been under treatment, since the disease has been completely eliminated. These are excellent results that considerably improve the patient's outlook on life.
We continue the treatment with Escozul™ with the intention of maintaining the results obtained and preventing the disease from recurring.
As we always say, it is important to point out that it is not possible to generalize any result with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.
It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.
If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, i.e. it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.
To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.
Prepared by LifEscozul™ Group May/2017
Medical Documents
Advanced Bladder Cancer Patient: Rickie Age: 52 years old
Escozul™™: patient with very advanced bladder cancer achieves tumor shrinkage in 8 months of treatment.
Read moreLet's start with the case description:
Rickie is a 52-year-old patient, diagnosed and operated in 2014 for bladder cancer. In the same year 2014 the disease recurred in left kidney and pancreas, despite chemotherapy. He came to us through his sister, who was desperately looking for an option that could give hope for her brother's health, after losing his padrea, flight and another sibling to cancer. Rickie had a poor prognosis for life, according to type of cancer, degree of progression and response to treatments.
We received the medical documentation of the case, verifying that it was a high grade papillary urothelial carcinoma of the bladder in stage IV (very aggressive), which had metastasized in the left kidney and in the tail of the pancreas, besides presenting involvement of lymph nodes in the abdomen and pelvis.
He presented bleeding in the urine and pain.
She was waiting to start a new immunotherapy treatment, with the hope of, together with Escozul™, being able to act against the disease.
Once the case was analyzed by our specialists, we informed the family about what they could expect with Escozul™ and the possibilities of achieving good results. In this case, given the characteristics of the disease, its evolution and progression, we hoped that we could perhaps slow down or stop its progression.
Each dose of Escozul™ is personalized, specific to the type of tumor and its aggressiveness. These doses can change over time according to the results observed in the patient. This requires an effective communication between the patient and our medical team to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us, then the results with Escozul™ will not be as expected.
Rickie started treatment with Escozul™ in March 2016.
Results and evolution:
Rickie started Escozul™ treatment with the help and support of his family.
His sister has always maintained frequent communication which has allowed our specialists to take the necessary steps to obtain the best possible results. Rickie started an immunotherapy treatment at the end of April.
In July 2016, 4 months into treatment, Rickie was doing well physically.
On scan performed in August, most of the lesions were stable, decrease in size of the renal nodule and slight growth in one of the nodules in abdomen. This is considered a mixed response to treatment, having achieved both stability and increase or decrease in size of different tumor lesions.
By September, Rickie had gained weight, looked well and the pain was under control.
In October, the new scan again showed stability of most of the lesions, with a decrease in size of the lesion in the tail of the pancreas, and a new slight increase in the mass in the kidney. The dose was increased and it was decided to wait for the results of the next scan.
In the last scan in December, the lymph node lesions were stable again, and it was observed that the lesion in the pancreas had decreased to 49mm (previously 64mm) and the kidney lesion to 41mm (previously 52mm).
It is considered at this time that the effect on Rickie is positive, since it has been possible to maintain the disease stable in general and even to reduce the size of the lesions. The evolution has not been a straight line because there have been moments of increase in the size of the lesions that have been controlled and subsequently reversed.
We are far from reaching a cure, and this is very difficult to obtain in such an advanced case with such an aggressive type of cancer, but the results obtained so far represent an increase in Rickie's life expectancy and also in his quality of life.
We continue with a progressive increase in dosage, with the intention of maintaining these results and helping Rickie to live many more years cancer free.
As we always say, it is important to note that it is not possible to generalize any results with Escozul™ to avoid creating false expectations in people, Escozul™ does not work miracles. Only working together and constant communication allow to keep the doses of Escozul™ personalized and functional against tumors.
It is also important to say that all the medical information of the case is available for consultation, as well as the contact with the medical counterpart of both the oncologist who attended the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.
If you wish to be treated under the Escozul™ Protocol, you should know the following: Escozul™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, that is, it cannot be sold. Each case that wishes to enter our protocol must be evaluated and approved because Escozul™ is not effective in all types of tumors. Once approved, the patient and his family members must commit to maintain a fluid contact with our medical team.
To enter the protocol you must send us an email to: servicios@lifescozulcuba.com indicating the patient's age, the type of cancer and the patient's physical and emotional state. This is the first step, and a specialist will take charge of the case. Our response time is an hour or two because each case is answered personally, not automatically. The idea is that the communication we establish is always governed by a professional and humane treatment.
Prepared by LifEscozul™ Group November/2016
Medical Documents
